- [ÀÇ·á°è´º½º] OECD, Çѱ¹º¸°ÇÀÇ·áü°è °ËÅ亸°í¼ ¹ßÇ¥
-
µî·ÏÀÏ : 2002.08.03
Á¶È¸¼ö : 1017
ÀÛ¼ºÀÚ : ¹Ú³ëÁØ
OECD, Çѱ¹º¸°ÇÀÇ·áü°è °ËÅ亸°í¼ ¹ßÇ¥
-------------------------------------------------------------------------------------
- ÀǾàºÐ¾÷ ¹× °Ç°º¸Çè °ü·Ã Æò°¡ ¹× Á¤Ã¥±Ç°í -
¡¼ºÙÀÓÀڷ᡽
¥°. OECD Çѱ¹º¸°ÇÀÇ·áü°è °ËÅ亸°í¼ ¿ä¾à¹®
¥±. OECD 16°³ ±Ç°í»çÇ×(±¹¹® ¹× ¿µ¹®)
¥². OECD º¸°ÇÀÇ·áü°èÆò°¡ °³¿ä
1. ÀÌ º¸°í¼´Â Çѱ¹º¸°ÇÀÇ·áü°èÀÇ ±¸¼º ¹× ÇüÆò¼º°ú È¿À²¼º Ãø¸é¿¡¼ÀÇ ¼º°ú¸¦ ºÐ¼®ÇÏ´Â °ÍÀÌ ¸ñÀûÀÓ. 2000³â 7¿ù¿¡ ÀÖÀº 2Â÷·ÊÀÇ °³Çõ (ÀǾàºÐ¾÷ ¹× °Ç°º¸Çè ÅëÇÕ)ÀÌ Çѱ¹ º¸°ÇÀÇ·áü°è¿¡ ¹ÌÄ£ ¿µÇâÀ» Æò°¡ÇÏ°í ÀÌÈÄ¿¡ ¹ß»ýÇÑ °Ç°º¸ÇèÀçÁ¤ À§±âÀÇ ¿øÀÎÀ» ÆľÇÇÏ°íÀÚ ÇÔ. ¶ÇÇÑ, °Ç°º¸Çè ÀçÁ¤ °ÇÀüÈ ¹× Çѱ¹º¸°ÇÀÇ·áü°èÀÇ ¹®Á¦Á¡ ±Øº¹ ¹æ¾ÈÀ» ±Ç°íÇÏ°í ÀÖÀ½. ¸¶Áö¸·À¸·Î, Àå±âÀûÀ¸·Î °Ç°º¸ÇèÁ¦µµ¿¡ ¹ÌÄ¥ ºÎÁ¤ÀûÀÎ ¿äÀΰú Á¦µµÀÇ °¡´ÉÇÑ ¹ßÀü ¹æ¾ÈÀÌ ¸ð»öµÇ°í ÀÖÀ½.
2. Çѱ¹Àº 60³â´ë ÀÌÈÄ ±Þ¼ÓÇÑ °æÁ¦¹ßÀü°ú »ê¾÷ȸ¦ ÀÌ·ç¾úÀ¸¸ç, ÀÌ¿Í µ¿½Ã¿¡ ±¹¹Îº¸°Ç°ú º¸°ÇÀÇ·áºÐ¾ß¿¡µµ °ý¸ñÇÒ¸¸ÇÑ º¯È°¡ ÀÖ¾úÀ½. Æò±Õ¼ö¸íÀÌ ¿¬ÀåµÇ¾úÀ¸¸ç ¿µ¾Æ »ç¸ÁÀ²µµ ²ÙÁØÈ÷ °¨¼ÒÇÏ°í ÀÖ°í, À¯º´À²°ú »ç¸Á·ü °ü·ÃÇÏ¿©¼µµ ±Þ¼ºÁúȯ¿¡¼ ¸¸¼ºÁúȯ(»ýÈ°½À°üº´)À¸·Î Áúº´ ±¸Á¶°¡ º¯ÇÏ¿´À½. °Ç°º¸ÇèÁ¦µµÀÇ ¼º°øÀûÀÎ µµÀÔÀ¸·Î ÀÇ·á¿¡ÀÇ Á¢±Ù¼ºÀÌ »ó´çÈ÷ È®´ëµÇ¾úÀ½. °Ç°º¸ÇèÀ» ±Ù·ÎÀÚ¿Í ÀÚ¿µÀÚ(±Ù·ÎÀÚ¿Í º¸Çè¿äÀ²°ú ÀçÁ¤»óÅ°¡ ÇöÀúÇÏ°Ô »óÀÌ)¿¡ ´ëÇÏ¿© Á¡ÁøÀûÀ¸·Î È®´ëÇÏ¿©, µµÀÔµÈ Áö ºÒ°ú 12³â¸¸ÀÎ
1989³â¿¡ Àü±¹¹Î Àû¿ëÀÌ ½ÇÇöµÇ¾úÀ½. Çѱ¹ Á¤ºÎ´Â ³·Àº ºñ¿ëÀ¸·Î Àü±¹¹Î¿¡°Ô °Ç°º¸Çè ÇýÅÃÀ» ºÎ¿©Çϱâ À§ÇÏ¿© ³·Àº º¸Çè·á, ³·Àº ±Þ¿©, ³ôÀº º»Àκδã(co-payment)À̶ó´Â Á¤Ã¥±âÁ¶¸¦ À¯ÁöÇÏ¿© ¿ÔÀ½.
3. Çѱ¹ÀÇ º¸°ÇÀÇ·áü°è´Â ¹Î°£ºÐ¾ß¿¡ ÀÇÇÏ¿© ÁÖµµµÇ°í ÀÖÀ¸¸ç, ¾à 90%ÀÇ ÀÇ»ç¿Í ´ëºÎºÐÀÇ º´»óÀÌ ¹Î°£ºÎºÐ¿¡¼ º¸À¯ÇÏ°í ÀÖÀ½. Á¤ºÎ´Â ÀǷἺñ½º Á¦°øÀڷμ ÇÑÁ¤µÈ ¿ªÇÒÀ» ¼öÇàÇÏ°í ÀÖÀ¸¸ç ¹Î°£ÀÇ·á½ÃÀå ±ÔÁ¦¿¡ ÀÖ¾î¼ ÀÚÀ¯¹æÀÓÁ¤Ã¥À» À¯ÁöÇÏ°í ÀÖÀ½. º¸°ÇÀÇ·á ÀçÁ¤Àº °ø°ø°ú ¹Î°£ÀÇ È¥ÇÕÇüÅ·Π±¸¼ºµÇ¾î ÀÖÀ¸¸ç, 1998³âÀÇ °æ¿ì OECD ±¹°¡ Æò±Õº¸´Ù ³·Àº 46%¸¸À» °ø°øºÎ¹®ÀÌ ºÎ´ãÇÏ¿´´Âµ¥, ÀÌ´Â ³ôÀº º»Àκδã±Ý ¹× ºñ±Þ¿© ¼ºñ½º¸¦ Àü¾× °³ÀÎÀÌ ºÎ´ãÇÏ°í Àֱ⠶§¹®ÀÓ. ȯÀÚµéÀº ÀÇ·á°ø±ÞÀÚ(provider, ÀÇ
»ç ¶Ç´Â º´¿ø)¸¦ ÀÚÀ¯·Ó°Ô ¼±ÅÃÇÒ ¼ö ÀÖÀ¸¸ç, ¾ç¹æ ¶Ç´Â ÇѹæÀÇ·á ¶ÇÇÑ ÀÚÀ¯·Ó°Ô ¼±ÅÃÇÒ ¼ö ÀÖÀ½. ÀÇ·á°ø±ÞÀڵ鿡 ´ëÇÑ ºñ¿ëº¸»óÀº ÇàÀ§º° ¼ö°¡Á¦(fee-for-service)·Î ¿î¿µµÇ°í ÀÖÀ½.
4. GDP¿¡¼ Â÷ÁöÇÏ´Â ±¹¹ÎÀÇ·áºñ(health expenditure) ºñÀ²(1999³â 5.4%)ÀÌ Çѱ¹°ú »ýÈ°¼öÁØÀÌ ºñ½ÁÇÑ ´Ù¸¥ OECD±¹°¡º¸´Ù ³·Àº ¼öÁØÀÎ °ÍÀ¸·Î ³ªÅ¸³ª°í ÀÖÀ¸³ª, 1987³â¿¡¼ 1999³âÀÇ ´ëºÎºÐÀÇ ±â°£µ¿¾È ÀÏÀÎ´ç ½ÇÁ¦ ±¹¹ÎÀÇ·áºñ´Â ÀÏÀÎ´ç ½ÇÁ¦ GDP Áõ°¡À² ÀÌ»óÀ¸·Î ±Þ¼ÓÈ÷ Áõ°¡ÇÏ¿´À½. 1990³â´ë Á߹ݱîÁö´Â Á¤ºÎ°¡ ÀϹݹ°°¡ »ó½ÂÀ²º¸´Ù º¸Çè¼ö°¡(medical fee)¸¦ ³·°Ô ÅëÁ¦ÇÏ¿´±â ¶§¹®¿¡ ÀÏÀÎ´ç ½ÇÁ¦ ±¹¹ÎÀÇ·áºñ Áõ°¡´Â °ÅÀÇ ÀüÀûÀ¸·Î ¾çÀûÀÎ Áõ°¡¿¡ ±âÀÎÇÔ. Çѱ¹Àº ¿©Å¸ OECD ±¹°¡µéº¸´Ù ±¹¹ÎÀÇ·áºñ¿¡¼ ¾àÁ¦
ºñ°¡ Â÷ÁöÇÏ´Â ºñÀ²ÀÌ »ó´çÈ÷ ³ô°í (¾à 30%), ÀÔ¿øȯÀÚ ºñ¿ëÀÌ ³·À½ (29%). ÇÑÀǻ縦 Æ÷ÇÔÇÑ °³¾÷ÀÇ»ç ¼ö´Â OECD¿¡¼ µÎ¹ø°·Î ³·À¸³ª, ÀÏÀδç Áø·á°Ç¼ö´Â ³ôÀ½. OECD±¹°¡ÀÇ Æò±Õº¸´Ù ±Þ¼º±â º´»ó¼ö´Â »ó´ëÀûÀ¸·Î ³ô°í Æò±Õ ÀÔ¿ø±â°£Àº ¸Å¿ì ³ôÀºµ¥, ÀÌ´Â ¼ö³â¿¡ °ÉÄ£ OECD ±¹°¡ÀÇ ÀϹÝÀûÀÎ Çö»ó°ú´Â ¹Ý´ëµÇ´Â °ÍÀÓ. ¸¸¼ºÁúȯÀ» À§ÇÑ ½Ã¼³°ú º´»óÀº ºÎÁ·ÇÑ ½ÇÁ¤ÀÓ.
5. Çѱ¹Àº 2000³â 7¿ù¿¡ °Ç°º¸ÇèÀÇ ÀçÁ¤Àû ÇüÆò¼º Á¦°í¸¦ À§ÇÏ¿© °Ç°º¸ÇèÀ» ÅëÇÕÇÏ¿´°í, ÀÇ»ç¿Í ¾à»çÀÇ ±â´ÉÀ» ºÐ¸®ÇÏ´Â ÀǾàºÐ¾÷À̶ó´Â µÎ °¡Áö °³ÇõÀ» ´ÜÇàÇÏ¿´À½. °³ÇõÀÇ Ãʱâ Æò°¡´Â ÀǾàÇ°, ƯÈ÷ Ç×»ýÁ¦ÀÇ Áö³ªÄ£ ¼Òºñ°¡ °¨¼ÒÇÏ°í ÀÖ´Â °ÍÀ» º¸¿©ÁÖ°í ÀÖÀ¸³ª, ÀǾàºÐ¾÷À¸·Î ÀÎÇÑ ÀÇ»çµéÀÇ ¾à°¡ ¸¶Áø Á¦°Å·Î ÀÇ»çµéÀÇ Àå±âÀûÀÎ Æľ÷ÀÌ ÃÊ·¡µÇ¾úÀ¸¸ç, ÀÌ¿¡ µû¶ó º¸Çè¼ö°¡°¡ 41%°¡ ÀλóµÇ¾úÀ½. °Ç°º¸Çè ÀçÁ¤À§±â´Â º¸Çè¼ö°¡ ÀλóÀ» Æ÷ÇÔÇÏ¿© ³ôÀº ¿Ü·¡È¯ÀÚ ¼öÁøÀ², ³ôÀº º¸Çè¾àÁ¦ºñ°¡ µ¿½Ã¿¡ ÀÛ¿ëÇÏ¿© ÃÊ·¡µÇ¾úÀ½. ¶ÇÇÑ, °³ÇõÁ¶Ä¡ ÀÌÀüºÎÅÍ °Ç°º¸Çè Á¦µµ¿¡ Àå±â°£¿¡ °ÉÃÄ ³»ÀçÇÏ°í ÀÖ´ø ÀûÀÚ ±¸Á¶µµ ÀçÁ¤ ¾ÇÈÀÇ ¿øÀÎÀ¸·Î ÀÛ¿ëÇÏ¿´À½.
6. º» º¸°í¼´Â Çѱ¹º¸°ÇÀÇ·áü°èÀÇ ÀåÁ¡°ú ´ÜÁ¡À» µ¿½Ã¿¡ °ËÅäÇÏ¿´´Âµ¥, ÀåÁ¡À¸·Î´Â °Ç°º¸ÇèÀÇ Àü±¹¹Î Àû¿ë°ú Àúºñ¿ë ±¸Á¶, ÀÇ·á°ø±ÞÀÚ ¼±ÅÃÀÇ ÀÚÀ²¼º, À¯±âÀûÀÎ °ø°ø ÀÏÂ÷º¸°ÇÀÇ·á¸Á(º¸°Ç¼Ò µî)µîÀ» µé ¼ö ÀÖÀ½. ±×·¯³ª, ¸î °¡Áö È¿°ú¼º Ãø¸é¿¡¼ °³¼±ÇÏ¿©¾ß ÇÒ ºÐ¾ß°¡ ÀÖÀ½. ù°·Î, »óÇÑÀÌ ¾ø´Â º»Àκδã·üÀº ¼Òµæ°èÃþ°£¿¡ º¸ÇèÀçÁ¤ ¹× Á¢±Ù¼º Ãø¸é¿¡¼ÀÇ ÇüÆò¼º ¹®Á¦¸¦ ¾ß±âÇÏ°í ÀÖÀ½. µÑ°·Î, °Ç°º¸Çè·á°¡ Ãß°¡ÀûÀÎ ±Þ¿©³ª Áõ°¡ÇÏ´Â ÀÇ·áÀÌ¿ëÀ» Á¶´ÞÇÒ ¸¸Å ÃæºÐÈ÷ ÀλóµÇÁö ¾Ê°í ÀÖÀ½. ¼Â°·Î, Áö¼Ó
°¡´ÉÇϰųª ¹Ù¶÷Á÷ÇÑ ¹æÇâÀÇ ±¹¹ÎÀÇ·áºñ Áõ°¡¿¡ ´ëÇÑ ÅëÁ¦ ÀåÄ¡°¡ ¾øÀ½. º¸Çè¼ö°¡ ÅëÁ¦°¡ ÁÖ¿äÇÑ ±¹¹ÎÀÇ·áºñ Áõ°¡ ¾ïÁ¦ ¼ö´ÜÀ¸·Î È°¿ëµÇ¾î ¿ÔÀ¸³ª, 90³â´ë ÈÄ¹Ý Æ¯È÷, ÀÇ»çµéÀÇ Æľ÷ÀÌÈÄ¿¡´Â ¼ö°¡ ÅëÁ¦ ±â´ÉÀÌ ¾àȵǾúÀ½. ³Ý°·Î, ÀÇ·áÀÇ Áú ±ÔÁ¦¿¡ ´õ ¸¹Àº ÁÖÀǸ¦ ±â¿ïÀÌ´Â °ÍÀÌ ¹Ù¶÷Á÷ÇÔ. ÀÓ»óÁø·á ±ÔÁ¦ ¹× ÀÚÀ²±ÔÁ¦°¡ ¸Å¿ì ÇÑÁ¤µÇ¾î ÀÖÀ¸¸ç, »ç½Ç¿¡ ±Ù°Å¸¦ µÐ Áø·á(evidence-based medicine)¸¦ ÃËÁøÇÏ°í ÀûÀýÄ¡ ¸øÇÑ ÀÇ·áÇàÀ§(unjustified variations in medical practice)¸¦ °¨¼Ò½ÃÅ°·Á´Â ³ë·ÂÀÌ ºÎÁ·ÇÏ¿´À½. ¸¶Áö¸·À¸·Î, ÃÖ±Ù °³Çõ¿¡¼ °æÇèÇÑ ¾î·Á¿òÀº Á¦µµ°ü¸® ü°è(governance)¸¦ °ÈÇÒ Çʿ伺ÀÌ ÀÖÀ½À» º¸¿©ÁÜ.
7. º» º¸°í¼´Â ÇöÇà Á¦µµÀÇ ¹®Á¦Á¡ °³¼±À» À§ÇÑ ¿©·¯ °¡Áö ±Ç°í¾ÈÀ» Á¦½ÃÇÏ°í Àִµ¥, ±Ç°í¾ÈµéÀº °³ÇõÀÌ Á¡ÁøÀûÀÎ Á¢±ÙÀ» ÅëÇÏ¿© ½ÃµµµÇ¾î¾ß ÇÔÀ» Á¦½ÃÇÏ°í ÀÖÀ½. ±Ç°í¾ÈµéÁß ÁÖ¿äÇÑ °ÍµéÀº ¾Æ·¡¿Í °°À½.
- °ú´ÙÇÑ ºñ¿ëÀÌ ¼Ò¿äµÇ´Â »óº´À¸·Î ÀÎÇÑ ÀçÁ¤Àû À§Çè º¸È£ °È
- °Ç°º¸Çè·á Àλó
- ÀÇ·á°ø±ÞÀÚÀÇ °úÀ×Áø·á ¾ïÁ¦¸¦ À§ÇÑ º¸ÇèÀÚ ±â´É °È(prudent purchasing of health services)
- ´Ù¾çÇÑ Áø·áºñ ÁöºÒÁ¦µµÀÇ Á¡ÁøÀû µµÀÔ
- ¿ä¾ç±Þ¿©ºñ¿ë Çù»ó(°è¾à) ÀýÂ÷ °³¼±
- ±Þ¿©ºñ ÁöÃâ °ü¸® °È
- ÀÇ·áÀÇ Áú Çâ»ó ¹× Àμ¾Æ¼ºê ºÎ¿© (ÀÓ»óÁø·á ¸ð´ÏÅ͸µ, È¿°úÀûÀÎ Áø·á¿¡ ´ëÇÑ º¸»ó ü°è, °ü·Ã Àü¹®°¡ Çùȸ¸¦ ÅëÇÑ ÀÚÀ²±ÔÁ¦ µîÀÇ ¹æ¹ý È°¿ë)
8. Àå±âÀûÀ¸·Î´Â »õ·Î¿î ÀÇ·á ºñ¿ëÀÇ Áõ°¡°¡ ¿¹»óµÉ ¼ö ÀÖÀ½. ÀÌ´Â ±Þ¼ÓÈ÷ Áõ°¡ÇÏ´Â ³ëÀÎ Àα¸¿Í °íºñ¿ëÀÇ ½ÅÀÇ·á ±â¼ú¿¡ ±âÀÎÇÔ. °Ç°º¸ÇèÁ¦µµ´Â ´õ ¸¹Àº °í¹ÎÀ» ¾È°Ô µÉ °ÍÀÓ.
9. ÀÌ·¯ÇÑ µµÀü¿¡ Á÷¸éÇÏ¿© Çѱ¹ÀÇ º¸°ÇÀÇ·áÁ¦µµ°¡ ¼·Î ´Ù¸¥ ¹æÇâÀ¸·Î ¹ßÀüÇÒ ¼ö ÀÖÀ½. µÎ °¡ÁöÀÇ ½Ã³ª¸®¿À°¡ ¿¹»óµÇ¸ç, ÀÌ »çÀÌ¿¡´Â ¸¹Àº °¡´É¼º ¶ÇÇÑ ÀÖÀ½. ù°·Î, º¸Çè·á¸¦ ³·°Ô À¯ÁöÇÏ¸ç º»Àκδã·üÀ» ³ôÀº ¼öÁØÀ¸·Î °è¼Ó À¯ÁöÇÏ´Â °ÍÀÌ°í, µÑ°´Â, ¿©Å¸ OECD ±¹°¡¿Í °°ÀÌ º¸Çè·á¸¦ ´ëÆø ¿Ã¸®°í º»Àκδã·üÀ» ³·Ãß´Â °ÍÀÓ. ÀÌ µÎ ½Ã³ª¸®¿À¿¡ µû¶ó ±ÔÁ¦ÀÇ ÀÇÀÇ, °ø±ÞÀÚ¿¡ ´ëÇÑ ÁöºÒº¸»ó Á¦µµ¿Í Á¤ºÎ ±ÔÁ¦ÀÇ À¯Çü°ú Á¤µµ´Â ´Ù¸¦ ¼ö ÀÖÀ½. ¼±ÅÃÀº Çѱ¹ ±¹¹Î°ú Á¤ºÎ¿¡ ´Þ·Á ÀÖÀ½. ±×·¯³ª, ¹Ì·¡ÀÇ ÁöÃâÁõ°¡
¿¡ ´ëÇÑ Àç¿øÁ¶´Þ ¹æ¹ý°ú ¹«°üÇÏ°Ô ±ÔÁ¦ÀûÀÌ°í Ã¥ÀÓ¼º Àִ üÁ¦ÀÇ °³¼±ÀÌ ÇÊ¿äÇÏ°Ô µÉ °ÍÀÓ.
1. Tackle financial barriers to access by introducing income-related annual caps on accumulated co-payments. (¼Òµæºñ·Ê ¿¬°£ º»ÀÎ ºÎ´ã±Ý »óÇÑ¾× Á¦µµ µµÀÔÀ¸·Î °æÁ¦Àû ÀÌÀ¯·Î ÀÎÇÑ ÀǷἺñ½º Á¢±Ù¼º ¹®Á¦ ÇؼÒ)
2. Increase the contribution rate in the near future to restore financial balance in the NHI. (°¡±î¿î Àå·¡¿¡ °Ç°º¸Çè ÀçÁ¤ ¼öÁö±ÕÇü ȸº¹À» À§ÇÑ °Ç°º¸Çè·á Àλó)
3. Introduce spending targets for NHI expenditure linked to forecast of revenue growth with 2-3 years perspective, and on this basis develop a clear negotiating position for fees. (2-3³â ÈÄ °Ç°º¸Çè ÀçÁ¤¼öÁö ±ÕÇü ¸ñÇ¥(¼öÀÔ ¿¹ÃøÄ¡¿Í ¿¬°èÇÑ ÀçÁ¤ÁöÃâ ¸ñÇ¥ ¼³Á¤)¿Í À̸¦ ±â¹ÝÀ¸·Î ÇÑ ¼ö°¡ Çù»ó¿¡¼ÀÇ ¸íÈ®ÇÑ ÀÔÀå Á¤¸³)
4. In addition, strengthens governments"s ability to control public expenditure on health by a gradual(negotiated) programme of provider payment reforms to develop mixed and hybrid payment systems in place of sole reliance on fee-for-service. (ÇàÀ§º° ¼ö°¡Á¦µµ¿¡ ´ë½ÅÇÏ´Â ´Ù¾çÇÑ ÁöºÒÁ¦µµ °³¹ßÀ» À§ÇÏ¿© Á¡ÁøÀûÀÎ ¼ö°¡Á¦µµ °³¼±À» ÅëÇÑ º¸°ÇºÎ¹®¿¡ ´ëÇÑ °ø°øÁöÃâ ´É·Â °È)
5. Promote cost effectiveness through more active and prudent purchasing of services and products by the NHI. (º¸ÇèÀÚ ±â´É °È(ÀǷἺñ½º ¹× Àåºñ µî Á¦Ç° ±¸¸Å ±â´É)¸¦ ÅëÇÑ ºñ¿ëÈ¿°ú¼º Çâ»ó À¯µµ)
6. Put greater emphasis on illness prevention and health promotion initiatives. (Áúº´¿¹¹æ°ú °Ç°ÁõÁø »ç¾÷¿¡ ´ëÇÑ Á¤Ã¥Àû °È À¯µµ)
7. Formalise rules for reimbursement of pharmaceuticals based on reference prices and, where available, the use of generic equivalents. (¾à°¡ »óȯ¿¡ ÀÖ¾î¼ÀÇ ÂüÁ¶°¡°ÝÁ¦ ¹× ´ëüÁ¶Á¦ µµÀÔ)
8. Implements policies to improve prescribing patterns based on prescript¡Úion guidelines, and systematic audit and appraisal of prescript¡Úion behaviors. (ó¹æ±âÁØ ¹× ó¹æ³»¿ë¿¡ ´ëÇÑ Ã¼°èÀûÀÎ Æò°¡¸¦ ÅëÇÑ Ã³¹æÇàÅ °³¼±)
9. To ensure continuing professional contestability for predomi- nantly privately-owned facilities, maintain the network of public health centres and selected public hospitals. (¹Î°£ºÎ¹®°ú °æÀ±¸ºÐµÇ´Â ¿ªÇÒ ¼öÇàÀ» À§ÇÑ º¸°Ç¼Ò¿Í °ø°øº´¿ø°£ ¿¬°èü°è À¯Áö)
10. Promote quality of care by strengthening and giving incentives to self-regulation and external performance measurement and improvements initiatives. (ÀÇ·áÀÇ Áú Çâ»óÀ» À§ÇÏ¿© ÀÇ·á±â°üÀÇ Áú Çâ»ó Á¶Ä¡, ¿ÜºÎ ¼º°ú Æò°¡ ¹× ÀÚ¹ßÀû ±ÔÁ¦¿¡ ´ëÇÑ Àμ¾Æ¼ºê ºÎ¿©)
11. Improve governance of the system, particularly by further developing regular and transparent negotiations between representatives of civil society, health insurers and providers and by improving accountability of the NHI and providers. (½Ã¹Î´Üü¡¤º¸ÇèÀÚ¡¤¼ºñ½º °ø±ÞÀÚ°£ÀÇ Á¤±âÀûÀÌ°í Åõ¸íÇÑ Çù»ó ¹× º¸ÇèÀÚ¡¤°ø±ÞÀÚÀÇ Ã¥ÀÓ¼º ÁõÁøÀ» ÅëÇÑ °Ç°º¸Çè °ü¸® ü°è °³¼±)
12. Improve data collection, especially in relation to quality, expenditure on drugs and medical services, and statistics on provider" gross and net income. (ÀÇ·áÀÇ Áú, ¾àÁ¦ ¹× ÀÇ·á ¼ºñ½º ºñ¿ë, °ø±ÞÀÚÀÇ ¼öÀÔ°ú °ü·ÃÇÑ Åë°è ¼öÁý ´É·Â Çâ»ó)
13. Improve the ability to analyse the consequences of changes to the system for contributors, patients and providers. (ÀÇ·á°ø±ÞÀÚ, º¸ÇèÀÚ, ȯÀÚ¿Í °ü·ÃµÈ Á¦µµ º¯°æ¿¡ µû¸¥ ¿µÇâ µî ºÐ¼® ´É·Â Çâ»ó)
14. In the longer term, if the NHI remains limited to a basic benefit package with high co-payments, private health insurance(PHI) coverage can be recommended for services excluded from the basic package but not for co
payments. "Gap-coverage" insurance should not be allowed.
However, medical savings account might play valuable role in allowing Korean to prepare for the rise in costs due to the inevitable ageing of the population. (Àå±âÀûÀ¸·Î °Ç°º¸ÇèÀÌ ³ôÀº º»Àκδã±ÝÀ» °è¼Ó À¯ÁöÇÑ´Ù¸é ºñ±Þ¿© ºÎºÐÀ» º¸ÀåÇÏ´Â ¹Î°£º¸Çè µµÀÔÀÌ ±Ç°íµÉ ¼ö ÀÖÀ¸³ª, º»Àκδã±Ý Â÷¾×À» º¸»óÇÏ´Â ¹Î°£º¸ÇèÀº Çã¿ëµÇ¾î¼´Â ¾ÈµÊ. ±×·¯³ª, ÀÇ·áÀúÃà°èÁ¤(MSA) µµÀÔÀÌ ³ëÀÎÀα¸ Áõ°¡¿¡ µû¶ó ´Ã¾î³ª´Â ÀÇ·áºñ ÁöÃâ ¾ïÁ¦¿¡ ÀÏÁ¤ ¿ªÇÒÀº ±â´ëµÊ)
15. If NHI is extended substantially to cover both more services and to reduce co-payments, action to strengthen cost control will be even more necessary. (ȹ±âÀûÀÎ ±Þ¿©È®´ë ¹× º»Àκδã±Ý °¨¼Ò Á¶Ä¡¸¦ µµÀÔÇÏ°íÀÚ ÇÑ´Ù¸é ºñ¿ëÅëÁ¦ ÀåÄ¡°¡ ´õ¿í °ÈµÇ¾î¾ß ÇÔ)
16. A gradual implementation approach to reforms will be pref- erable to "big bang" reforms. (±ÞÁøÀûÀÎ °Íº¸´Ù´Â Á¡ÁøÀûÀÎ °³ÇõÀÌ ¹Ù¶÷Á÷ ÇÔ)
¡à OECD Çѱ¹ º¸°ÇÀÇ·áü°è Æò°¡ °³¿ä
¡Û Æò°¡¿äû ¸ñÀû
- ÀǾàºÐ¾÷ ½Ç½Ã, ÀǾàÇ° À¯Åë°ü¸®Ã¼°è °³Çõ ¹× °Ç°º¸ÇèÁ¦µµ ÅëÇÕ µî ¿ì¸® ³ª¶ó º¸°ÇÀÇ·áü°è Àü¹Ý¿¡ ´ëÇÑ OECDÀÇ °´°üÀû Æò°¡¸¦ ÅëÇØ º¸°ÇÀÇ·áü°è °³¼± ¹æÇâ ¸ð»ö
¡Û OECDÀÇ Æò°¡´ë»ó
- º¸°ÇÀÇ·áü°èÀÇ À塤´Ü±â ¹®Á¦Á¡ ¹× Á¦µµÀû Ư¡ ºÐ¼®
- º¸°ÇÀÇ·áü°è Àü¹ÝÀÇ È¿À²¼º(Efficiency)°ú ÇüÆò¼º(Equity) Æò°¡
- ƯÈ÷, º¸°ÇÀÇ·áü°è ¹× ÃÖ±ÙÀÇ °³ÇõÁ¶Ä¡(ÀǾàºÐ¾÷ ¹× °Ç°º¸Çè ÅëÇÕ)ÀÇ °á°ú¿¡ ´ëÇÏ¿© ºÐ¼®
¡Û Æò°¡±â°£ : 2001. 7 - 2002. 6(1³â°£)
¡Û Àç¿ø(ÀÚ¹ßÀû ±â¿©±Ý) : 456õ FF (¾à 87¹é¸¸¿ø)
----------º¹ÁöºÎ ¿¹»ê????????-------------
¡Ø OECD º¸°ÇÇÁ·ÎÁ§Æ®(Health Project)
¡Û OECD´Â ȸ¿ø±¹µéÀÇ Àα¸ °í·ÉÈ ¹× ±¹¹ÎÀÇ·áºñ ÁöÃâ Áõ°¡¿¡ ´ëºñ, ȸ¿ø±¹ º¸°ÇÀÇ·á Á¤Ã¥À» Á¾ÇÕÀûÀ¸·Î °ËÅäÇϱâ À§ÇØ Health Project »ç¾÷À» ÃßÁøÁß
- º¸°Ç»ç¾÷Ưº°ÀÛ¾÷¹ÝȸÀÇ(Ad hoc Group Meeting on Health Project)¸¦ ±¸¼ºÇÏ¿© 3°³³â »ç¾÷("01-"03)À¸·Î ÃßÁø
¡Û ÁÖ¿ä»ç¾÷ ºÐ¾ß´Â ÀǷẸ°Çü°è ¼º°ú Æò°¡(Part A), º¸°ÇÀÇ·áü°è ¼º°ú Â÷ÀÌ ºÐ¼®(Part B), Àå±â¿ä¾ç´ëÃ¥(Part C), º¸°ÇÀÇ·áü°èÀÇ Á¾ÇÕÀû Æò°¡(Part 4)·Î ±¸¼º(4°³ ºÐ¾ß 6°³»ç¾÷)
¡à ÃßÁø °æ°ú
¡Û 2001. 5. : OECD¿¡ ¾Æ±¹ º¸°ÇÀÇ·áü°èÆò°¡ ¿äû(Àå°ü °øÇÑ)
¡Û 2001. 6. : OECD º¸°Ç Project ¹× ¾Æ±¹ º¸°ÇÀÇ·áü°èÆò°¡ ´ëºñ¸¦ À§ÇÑ °ü·Ã Àü¹®°¡ Network ±¸¼º
¡Û 2001. 8¡9. : OECDÀÇ ¼³¹®¼ ÀÛ¼º Á¦Ãâ (10°³ ºÐ¾ß 173°³ ¹®Ç×)
¡Û 2001³â 9. : OECD Æò°¡´Ü ¹æÇÑ, ÇöÁö Æò°¡
- Æò°¡´Ü(3¸í) : Hyung-Sun Jeong, Francesca Colombo, Jeremy Hurst
================ (ÀÌ »ç¶÷ ¼Ò¼Ó ¾îµð³Ä???????)
¡Û 2001. 12. : "OECD ±¹°¡µéÀÇ º¸°ÇÀÇ·áü°è ¼º°úÃøÁ¤ Çâ»ó"¿¡ °üÇÑ ¿ÀŸ¿Í ȸÀÇ Âü°¡
- ÁÖ¿äÀÇÁ¦ : º¸°ÇÀÇ·áü°è Æò°¡ °ü·Ã °¢±¹ °æÇèÀÇ °øÀ¯
- Âü°¡ÀÚ(10¸í) : ¹ÚÇÏÁ¤(º¸ÇèÁ¤Ã¥°úÀå) µî º¹ÁöºÎ °ü°èÀÚ 4ÀÎ, Á¶Àç±¹(º¸»ç¿¬) ±è⿱
=======================================================================================
(¼¿ï´ë) µî °ü°èÀü¹®°¡ 6ÀÎ
¡Û 2002. 4. : OECD Á¦2Â÷ º¸°Ç»ç¾÷Ưº°ÀÛ¾÷¹Ý ȸÀÇ Âü°¡
- ÁÖ¿äÀÇÁ¦ : ¾Æ±¹ º¸°ÇÀÇ·áü°è Æò°¡ ÃÊ¾È °ËÅä
- Âü°¡ÀÚ(5¸í) : ÃÖÈñÁÖ(±¹Á¦Çù·Â´ã´ç°ü), ¿ÕÁøÈ£(¾à¹«½ÄÇ°Á¤Ã¥°úÀå), ¾ç¼ºÀÏ(º¸ÇèÁ¤Ã¥°ú), Á¶Àç
±¹(º¸»ç¿¬), ¹ÚÃá½Ä(±¹¹Î°Ç°º¸Çè°ø´Ü)
¡Û 2002. 7. : OECD ÃÖÁ¾ Æò°¡º¸°í¼ ¿ì¸®ºÎ¿¡ Á¦Ãâ
< Âü°íÀÚ·á, OECD Health Project »ç¾÷³»¿ë: 4°³ ºÐ¾ß 6°³ »ç¾÷>
¡Û Part A (ÀǷẸ°Çü°è ¼º°úÃøÁ¤ ¹× °³¼±)
- º¸°ÇÀÇ·áü°è¿¡ ´ëÇÑ »ý»ê¼º Æò°¡, È¿À²¼º°ú ÇüÆò¼º µî Á¾ÇÕÀû ÁöÇ¥¸¦ ¹Ý¿µÇÑ Àç¿øµ¿¿ø°ú ÀÇ·á
Àü´Þü°è µî º¸°ÇÀÇ·áü°è¿¡ ´ëÇÑ ÃøÁ¤
¡Û Part B (º¸°ÇÀÇ·áü°èÀÇ ¼º°ú Â÷ÀÌ ¿äÀÎ ºÐ¼®)
1) º¸°ÇÀÇ·á ÀÚ¿øÈ°¿ë(Resource Use)ÀÇ ¹Ì½ÃÀû È¿À²¼º
- ÀÇ»çÀÇ °ü¸®Ã¼°è ¹× ÀÇ·á±â°üÀÇ ¿î¿µ½Ã½ºÅÛÀÌ º¸°ÇÀÇ·áü°èÀÇ ¼º°ú ¹× Â÷ÀÌ¿¡ ¹ÌÄ¡´Â ¿µÇâ
2) ¹Î°£ÀǷẸÇè(Private Health Insurance)ÀÇ ¿ªÇÒ Æò°¡
- º¸ÇèÀÚ, Àç¿ø, °¡ÀÔÀÇ °Á¦¼º ¿©ºÎ, ÀçºÐ¹è µî ¹Î°£º¸ÇèÀÇ º¸¿ÏÀû ¿ªÇÒ µîÀÇ ºÐ¼® ¹× Æò°¡
3) »ý¸í°øÇÐ µî ÀÇ·áºÐ¾ß °ü·Ã ½Å±â¼úÀÇ °æÁ¦¡¤»çȸÀû ¿µÇâºÐ¼®
- »ý¸í°øÇÐ µî ½ÅÀÇ·á±â¼ú¿¡ ´ëÇÑ È¸¿ø±¹µéÀÇ Á¤Ã¥ ¹× ¿¬±¸ÃßÁøµ¿Çâ°ú µ¿ ºÐ¾ß°¡ º¸°ÇÀÇ·áü°è
¿¡ ¹ÌÄ¡´Â ¿µÇâ
¡Û Part C (Àå±â¿ä¾ç ´ëÃ¥)
- °í·ÉÀÚ, Ä¡¸Å³ëÀεî Àå±âÄ¡·á ÇÊ¿äÀÚ¿¡ ´ëÇÑ È¿°úÀûÀÎ Á¤Ã¥¹æ¾È
- ³ëÀμº Ä¡¸ÅÀÇ »çȸÀû ÇÔÀÇ ¹× Á¤Ã¥Àû Á¢±ÙÀ» À§ÇÑ Case Study
¡Û Part D (ÀǷẸ°Çü°èÀÇ Á¾ÇÕÆò°¡)
- °¢±¹ º¸°ÇÀÇ·áü°èÀÇ ¼º°ú(Performance) °áÁ¤¿äÀÎ ºÐ¼®
- ½Å±Ôȸ¿ø±¹ ¹× ÃÖ±Ù Áß¿ä°³Çõ Á¶Ä¡°¡ ÁøÇàµÈ ȸ¿ø±¹ µî¿¡ ´ëÇÑ º¸°ÇÀÇ·áü°èÀÇ ±¹º° °ËÅä
(Country Reviews) ½Ç½Ã